{"id":74292,"date":"2026-04-20T18:23:09","date_gmt":"2026-04-20T12:53:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=74292"},"modified":"2026-04-20T18:23:11","modified_gmt":"2026-04-20T12:53:11","slug":"jubilant-pharmova-q4-results-2026-date-revenue-pat-amp-analyst-outlook","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/jubilant-pharmova-q4-results-2026-date-revenue-pat-amp-analyst-outlook\/","title":{"rendered":"Jubilant Pharmova Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook"},"content":{"rendered":"

Jubilant Pharmova (NSE: JUBLPHARMA) is preparing to announce its Q4 FY26 (January\u2013March 2026) financial results for the period ended March 31, 2026. With the stock trading at Rs 580 \u2014 against a 52-week high of Rs 820 and a 1-year return of -18% \u2014 the Q4 FY26 results will be a pivotal event for investors assessing their position heading into FY27.<\/p>

Analyst consensus estimates for Q4 FY26 stand at Rs 2,200\u20132,400 Cr in revenue and Rs 90\u2013120 Cr in profit after tax, with margin expectations of EBITDA 14\u201316%. The key growth metric of Radiopharma Revenue +20\u201325% YoY will be closely watched alongside the management’s FY27 guidance \u2014 which analysts consider more important than the reported Q4 number in the current macro environment.<\/p>

Get free investment predictions and live Q4 result alerts on Univest<\/strong><\/a>.<\/p>

Jubilant Pharmova Q4 Results 2026 Date<\/p>

The Jubilant Pharmova Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to consider and approve the audited consolidated and standalone financial results for the quarter and full year ended March 31, 2026.<\/p>

Here is the broader Q4 FY26 earnings calendar for major Indian companies:<\/p>

Company<\/strong><\/td>Results Date<\/strong><\/td>Key Watch<\/strong><\/td><\/tr>
TCS<\/td>Apr 9, 2026 \u2713<\/td>Q4 PAT Rs 13,718 Cr, dividend Rs 31<\/td><\/tr>
HDB Financial<\/td>Apr 15, 2026 \u2713<\/td>First listed results, AUM and dividend<\/td><\/tr>
Wipro<\/td>Apr 16, 2026 \u2713<\/td>FY27 IT guidance; buyback decision<\/td><\/tr>
HDFC Bank<\/td>Apr 18, 2026 \u2713<\/td>NIM recovery; chairman transition<\/td><\/tr>
ICICI Bank<\/td>Apr 18, 2026 \u2713<\/td>NPA quality; loan growth guidance<\/td><\/tr>
Infosys<\/td>Apr 23, 2026<\/td>FY27 CC revenue guidance (critical)<\/td><\/tr>
IndusInd Bank<\/td>Apr 24, 2026<\/td>Derivative restatement resolution<\/td><\/tr>
Coal India<\/td>Apr 27, 2026<\/td>Volume + dividend; sector watch<\/td><\/tr><\/tbody><\/table><\/figure>

For more Q4 FY26 results previews across all sectors, visit Univest Blogs<\/strong><\/a>.<\/p>

Why This Quarter Matters<\/p>

Q4 FY26 (January\u2013March 2026) is the most important quarter of any financial year \u2014 it determines the full-year FY26 financial outcome, sets the earnings base for FY27 analyst estimates, and triggers final dividend announcements. For Jubilant Pharmova, with a 1-year stock return of -18%, this quarter’s results and FY27 guidance are critical for determining whether the stock can begin a meaningful recovery or faces continued pressure.<\/p>

Beyond the headline revenue and PAT numbers, investors will focus on three things: (1) whether FY27 guidance matches the consensus expectation of Radiopharma Revenue +20\u201325% YoY, (2) whether the margin of EBITDA 14\u201316% is sustainable or under pressure, and (3) the dividend announcement of Nil. A positive surprise on any two of these three parameters could drive a meaningful post-results re-rating.<\/p>

Jubilant Pharmova Q4 FY26 Earnings Estimates<\/p>

\"\"<\/figure>

Figure 2: Jubilant Pharmova Q4 FY26 Analyst Estimates \u2014 Revenue: Rs 2,200\u20132,400 Cr | PAT: Rs 90\u2013120 Cr | Margin: EBITDA 14\u201316% | Growth: Radiopharma Revenue +20\u201325% YoY<\/p>

Access premium SEBI-registered research on Univest<\/strong><\/a>.<\/p>

Brokerages including MOFSL, YES Securities, and JM Financial have published their Q4 FY26 preview estimates for Jubilant Pharmova. The consensus projects Rs 2,200\u20132,400 Cr in revenue (versus Q3 FY26 actual of Rs 2,100 Cr) and PAT of Rs 90\u2013120 Cr (versus Q3 actual of Rs 95 Cr). A beat on revenue combined with margin expansion would be the most positive scenario for the stock.<\/p>

Metric<\/strong><\/td>Q3 FY26 Actual<\/strong><\/td>Q4 FY26 Estimate<\/strong><\/td>Key Watch<\/strong><\/td><\/tr>
Revenue<\/td>Rs 2,100 Cr<\/td>Rs 2,200\u20132,400 Cr<\/td>Sequential growth trajectory<\/td><\/tr>
PAT<\/td>Rs 95 Cr<\/td>Rs 90\u2013120 Cr<\/td>Clean earnings quality<\/td><\/tr>
EBITDA \/ Margin<\/td>EBITDA 15%<\/td>EBITDA 14\u201316%<\/td>Input cost and pricing power<\/td><\/tr>
Key Growth Metric<\/td>Q3 base<\/td>Radiopharma Revenue +20\u201325% YoY<\/td>Volume \/ Rate \/ SSG<\/td><\/tr>
Dividend (Expected)<\/td>N\/A<\/td>Nil<\/td>FCF signal to market<\/td><\/tr><\/tbody><\/table><\/figure>

Screen Jubilant Pharmova<\/strong><\/a> live fundamentals, FII\/DII activity, and analyst upgrades on Univest Screener.<\/p>

5 Key Factors That Will Drive Jubilant Pharmova Q4 FY26 Performance<\/p>

1. Q4 FY26 Revenue Estimate: Rs 2,200\u20132,400 Cr<\/p>

Analyst consensus expects Jubilant Pharmova to report Rs 2,200\u20132,400 Cr in Q4 FY26. Radiopharma Revenue +20\u201325% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.<\/p>

2. PAT Estimate and Margin Trajectory<\/p>

Analyst consensus expects Jubilant Pharmova to report Rs 2,200\u20132,400 Cr in Q4 FY26. Radiopharma Revenue +20\u201325% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.<\/p>

3. Key Growth Driver: Radiopharma Revenue +20\u201325% YoY<\/p>

Analyst consensus expects Jubilant Pharmova to report Rs 2,200\u20132,400 Cr in Q4 FY26. Radiopharma Revenue +20\u201325% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.<\/p>

4. Dividend and Capital Allocation<\/p>

Analyst consensus expects Jubilant Pharmova to report Rs 2,200\u20132,400 Cr in Q4 FY26. Radiopharma Revenue +20\u201325% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.<\/p>

5. FY27 Guidance \u2014 The Most Critical Catalyst<\/p>

Analyst consensus expects Jubilant Pharmova to report Rs 2,200\u20132,400 Cr in Q4 FY26. Radiopharma Revenue +20\u201325% YoY is the key metric tracked by the Street. Track live financials on Univest Screener.<\/p>

5 Risks to Watch in Jubilant Pharmova Q4 FY26<\/p>

1. US Tariff Macro Headwinds<\/p>

The 26% US reciprocal tariff on Indian goods \u2014 announced April 2, 2026 \u2014 has created FII outflow pressure across Indian equities. For Jubilant Pharmova, indirect impacts include lower institutional ownership and compresed earnings multiples even if the company’s own exports or supply chain are not directly affected.<\/p>

2. Results Miss Versus Estimates<\/p>

If Jubilant Pharmova’s Q4 FY26 results miss analyst estimates of Rs 2,200\u20132,400 Cr revenue and Rs 90\u2013120 Cr PAT, the stock could correct sharply. Investors should have pre-defined exit levels and position sizing appropriate for the earnings uncertainty.<\/p>

3. FY27 Guidance Disappointment<\/p>

If management’s FY27 guidance falls below the Street’s expectations \u2014 even with an in-line Q4 \u2014 the stock may decline on forward estimate cuts. Guidance credibility is a function of track record; any slippage from prior guidance makes the market discount new guidance aggressively.<\/p>

4. Sector-Level Competitive Pressure<\/p>

The Pharma \/ Radiopharmacy \/ CDMO sector faces intensifying competitive dynamics from both domestic capacity additions and international competition. Jubilant Pharmova’s ability to maintain pricing power and market share in this environment is a critical long-term risk factor.<\/p>

5. FII Selling and Liquidity Risk<\/p>

With FII holding at varying levels, global risk-off events can trigger concentrated institutional selling that disconnects price from fundamentals. Mid-and small-cap stocks are particularly vulnerable to liquidity-driven moves on results day.<\/p>

Jubilant Pharmova Share Price and Analyst Ratings<\/p>

Jubilant Pharmova is trading at Rs 580 as of April 2026, against a 52-week high of Rs 820 and a 52-week low of Rs 480. The 1-year return of -18% reflects the macro headwinds of FY26 \u2014 US-India tariff uncertainty, FII outflows, and sector-specific pressures. Analyst consensus 12-month targets range from Rs 680 to Rs 750, implying potential recovery from current levels contingent on Q4 FY26 execution and FY27 guidance.<\/p>

Brokerage<\/strong><\/td>Rating<\/strong><\/td>12M Target<\/strong><\/td>Investment Thesis<\/strong><\/td><\/tr>
MOFSL<\/td>Buy<\/td>Rs 750<\/td>US radiopharma PSMA expansion<\/td><\/tr>
JM Financial<\/td>Buy<\/td>Rs 720<\/td>CDMO order wins H2 FY26<\/td><\/tr>
YES Securities<\/td>Neutral<\/td>Rs 680<\/td>Allergy therapy volume watch<\/td><\/tr><\/tbody><\/table><\/figure>

Download the Univest iOS App<\/strong><\/a> or Univest Android App<\/strong><\/a> to track Jubilant Pharmova live price, charts, and receive real-time research alerts from SEBI-registered analysts.<\/p>

Conclusion<\/p>

Jubilant Pharmova Q4 FY26 results on May 2026 (Expected) will be a key earnings event for investors monitoring the Pharma \/ Radiopharmacy \/ CDMO sector. With analyst consensus projecting revenue of Rs 2,200\u20132,400 Cr and PAT of Rs 90\u2013120 Cr, the stock at Rs 580 offers a risk-reward profile that depends on execution delivery and FY27 guidance credibility. FY27 guidance \u2014 revenue growth bands, margin targets, and capex plans \u2014 will be the single most important post-results catalyst. For more Q4 FY26 previews, visit <\/p>

Univest Blogs<\/strong><\/a>.<\/p>

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions. For more Q4 FY26 results previews, visit Univest Blogs.<\/p>

Frequently Asked Questions<\/p>

Q: What is the Jubilant Pharmova Q4 results 2026 date?<\/p>

The Jubilant Pharmova Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve the audited Q4 FY26 financial results and consider a final dividend recommendation.<\/p>

Q: What is the Jubilant Pharmova Q4 FY26 PAT estimate?<\/p>

Analysts estimate Jubilant Pharmova Q4 FY26 PAT in the range of Rs 90\u2013120 Cr, based on revenue of Rs 2,200\u20132,400 Cr and margin of EBITDA 14\u201316%. Actual results may differ from consensus estimates.<\/p>

Q: What is Jubilant Pharmova’s share price ahead of Q4 results?<\/p>

Jubilant Pharmova is trading at Rs 580 as of April 2026. The 52-week high is Rs 820 and the 52-week low is Rs 480. The 1-year return is -18% and market capitalisation is Rs 9,300 Cr.<\/p>

Q: Will Jubilant Pharmova declare a dividend in Q4 FY26?<\/p>

Jubilant Pharmova is expected to consider Nil at the Q4 FY26 board meeting. The quantum will be confirmed on the results date.<\/p>

Q: Which analysts have a Buy rating on Jubilant Pharmova?<\/p>

MOFSL (target Rs 750), JM Financial (target Rs 720). Consult a SEBI-registered financial advisor before making any investment decision.<\/p>

Q: What were Jubilant Pharmova Q3 FY26 results?<\/p>

Jubilant Pharmova reported Q3 FY26 revenue of Rs 2,100 Cr and PAT of Rs 95 Cr, with margin at EBITDA 15%. These Q3 actuals form the sequential base against which Q4 FY26 estimates are benchmarked.<\/p>

Q: When do Infosys and TCS announce Q4 results 2026?<\/p>

TCS declared Q4 FY26 results on April 9, 2026 \u2014 reporting PAT of Rs 13,718 crore and revenue of Rs 70,698 crore. For the full TCS preview visit https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview. Infosys Q4 FY26 results are scheduled for April 23, 2026 \u2014 FY27 CC revenue guidance is the critical watch. Read the full analysis at https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview.<\/p>

Q: Is Jubilant Pharmova a good investment ahead of Q4 results?<\/p>

This depends on your risk appetite, investment horizon, and portfolio context. Jubilant Pharmova has both compelling factors \u2014 US radiopharma PSMA expansion \u2014 and genuine near-term risks including US tariff macro headwinds and FY27 guidance uncertainty. Analyst consensus targets range from Rs 680 to Rs 750. Consult a SEBI-registered financial advisor before investing.<\/p>

Recent Article<\/strong><\/h2>

Natural Capsules Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook<\/a><\/p>

National Fertilizers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook<\/a><\/p>

National Aluminium Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>

Nath Bio-Genes (India) Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook<\/a><\/p>

Narmada Agrobase Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Jubilant Pharmova (NSE: JUBLPHARMA) is preparing to announce its Q4 FY26 (January\u2013March 2026) financial results for the period ended March 31, 2026. With the stock trading at Rs 580 \u2014 against a 52-week high of Rs 820 and a 1-year return of -18% \u2014 the Q4 FY26 results will be a pivotal event for investors<\/p>\n","protected":false},"author":27,"featured_media":74299,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3862],"class_list":["post-74292","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results-expectations"],"metadata":{"_edit_lock":["1776689722:27"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:4:{s:63:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1198.jpeg\";a:2:{s:2:\"id\";i:74293;s:11:\"source_type\";s:13:\"media-library\";}s:72:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1198-1024x536.jpeg\";a:2:{s:2:\"id\";i:74293;s:11:\"source_type\";s:13:\"media-library\";}s:95:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20182009\/image-1198.jpeg\";a:2:{s:2:\"id\";i:74293;s:11:\"source_type\";s:13:\"media-library\";}s:104:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20182009\/image-1198-1024x536.jpeg\";a:2:{s:2:\"id\";i:74293;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["79"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_focus_keyword":["Jubilant Pharmova"],"_thumbnail_id":["74299"],"_edit_last":["27"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8573"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20182130\/Jubilant-Pharmova-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/74292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=74292"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/74292\/revisions"}],"predecessor-version":[{"id":74301,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/74292\/revisions\/74301"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/74299"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=74292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=74292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=74292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}